PHILADELPHIA and OXFORDSHIRE, United Kingdom, 6 August 2020 (GLOBE NEWSWIRE) – Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in mobile cancer therapy, published its monetary effects and provided a commercial update for the quarter ending On June 30, 2020.
“We reported responses on various types of forged tumors during the 2020 trimester, demonstrating the possibility that SPEAR T cells will bring benefits to others with cancer. We also raised capital, placing us in a strong monetary position to continue executing our strategic plans,” said Adrian Rawcliffe, CEO of Adaptimmune. “Despite the effect of the COVID-19 pandemic on the biotechnology industry, we have made smart progress in our arrangements for the launch of our first product in the United States in 2022 for patients with sarcoma, while launching and making new Phase 2 Clinical Trials plans. However, as we enter the part of the year, we expect COVID-19 to continue to have an effect and largely track developments.
PLANNED MILESTONES 2S 2020
CLINICAL UPDATES
MANUFACTURE AND SUPPLY
FUNDING
Financial effects for the three- and six-month periods ended June 30, 2020
Financial guidance
Conference call information and online information The company will host a live teleconvention at 8:00 am EDT (1:00 BST) today, August 6, 2020. The live broadcast of the call to the convention will take place in the investor segment of the Adaptimmune website. in www.adaptimmune.com. A file will be filed after the call at the same address. To participate in the live convention, dial (833) 652-5917 (USA. Or Canada) or (430) 775-1624 (international). After making the call, request that it be attached to the Adaptimmune convention call and provide the confirmation code (5488705).
About Adaptimmune Adaptimmune is a clinically stage biopharmaceutical company that specializes in the progression of new cancer immunotherapy products for others with cancer. The company’s unique T-cell platform, SPEAR® (enhanced affinity receptor with specific peptides) allows T-cell engineering to target and destroy cancer in various forged tumors.
Forward-looking statements This press release “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain dangers and insecurities. These hazards and insecurities can make our actual effects differ materially from those indicated through these forward-looking statements, including, but not limited to: success, burden and timing of our product progression and clinical trial activities and our ability to effectively advance our TCR. through regulatory and marketing processes. For a more detailed description of the dangers and insecurities that may cause our actual effects to differ materially from those expressed in those forward-looking statements, as well as the dangers associated with our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on May 14, 2020 and our other filings with the SEC. The forward-looking statements contained in this press release refer only to the date on which they were made and we assume no legal responsibility to update such forward-looking statements to reflect long-term occasions or circumstances.
Total liquidity (a non-GAAP monetary measure) Total liquidity (a non-GAAP monetary measure) is total money and money equivalents and marketable securities. Each of these pieces appears on the condensed consolidated balance sheet. The U.S. GAAP monetary measure Directly comparable to general liquidity is money and money equivalents presented in abstract consolidated monetary statements, which are close to overall liquidity as follows (in millions):
Condensed consolidated earnings statement (unaudited, in thousands, consistent with consistent percentage data)
Condensed consolidated balance sheets (unaudited inventory data, in thousands)
Condensed consolidated cash flow table (unaudited, in thousands)
Adaptimmune is a clinically stage biopharmaceutical company that specializes in the progression of new cancer immunotherapy products for others with cancer. The company’s unique T-cell platform, SPEAR® (enhanced affinity receptor with specific peptides) allows T-cell engineering to target and destroy cancer in various forged tumors.
Forward-looking statements This press release “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain dangers and insecurities. These hazards and insecurities can make our actual effects differ materially from those indicated through these forward-looking statements, including, but not limited to: success, burden and timing of our product progression and clinical trial activities and our ability to effectively advance our TCR. through regulatory and marketing processes. For a more detailed description of the dangers and insecurities that may cause our actual effects to differ materially from those expressed in those forward-looking statements, as well as the dangers associated with our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on May 14, 2020 and our other filings with the SEC. The forward-looking statements contained in this press release refer only to the date on which they were made and we assume no legal responsibility to update such forward-looking statements to reflect long-term occasions or circumstances.
Adaptimmune Contacts:
Media Relations:
Investor Relations:
Dr. Juli P. Miller – Senior Director, Investor Relations T: ‘1215825 9310M:’ 1215460 [email protected]
1 Total liquidity is a non-GAAP monetary measure that is explained and reconciled with the comparable maximum monetary measures listed in accordance with GAAP below.